Trials / Completed
CompletedNCT00937859
Treatment of Patients With Nocturia
A Phase III Randomized, Double Blind, Placebo Control, Multicenter Study to Investigate the Efficacy and Safety of SER120 Nasal Spray Formulation in Patients With Nocturia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 301 (actual)
- Sponsor
- Serenity Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate a treatment of nocturia. The hypothesis is that SER120 will decrease the number of nocturic episodes compared to placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SER120 | SER120 |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2009-06-01
- Primary completion
- 2010-07-01
- Completion
- 2010-07-01
- First posted
- 2009-07-13
- Last updated
- 2020-09-18
- Results posted
- 2020-09-18
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00937859. Inclusion in this directory is not an endorsement.